In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Opens Up: Can Industry Live With Greater Transparency?

Executive Summary

Drug sponsors are finding little to like about FDA’s transparency initiative - especially proposals that would allow the agency to disclose more about products still in development. But given the public interest in greater transparency - and FDA’s interest in avoiding another Avandia - industry needs to decide whether this is a fight worth having. This article was originally published in the July/August 2010 issue of The RPM Report.

You may also be interested in...



Opening Up the Black Box: FDA Wants To Make "Complete Response" Letters Public

FDA's transparency initiative is starting to take shape. While many industry executives see the value in making more information available to the public, one idea makes them nervous: publicizing the letters FDA sends when it declines to approve a new drug or biologic. Top FDA officials already support making "complete response" letters public, and the Commissioner's office is open to the idea. How should industry prepare?

The FDA Roundtable Part I: The Regulators' View of Drug Development

Three top FDA officials sat down with The RPM Report at their White Oak campus to discuss the top drug regulatory issues. On the table for discussion: drug safety, comparative effectiveness and the future of drug development.

Tracking Troubled NDAs: New FDA Regs Mean Less Clarity for Investors

After an 11-year process, FDA is doing away with "approvable" and "not approvable" letters. . The new name ("complete response") gets rid of the negative connotations of "not approvable". But it is likely to create more confusion-and less transparency--for investors and the public.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel